Evis Bioscience raises €422K Seed round
16 December 2025· Schlieren, Switzerland· biotech, gene_therapy, drug_delivery, nanotechnology, materials, b2b
To accelerate EVis Bioscience AG's research and development initiatives, including further enhancing sophisticated laboratory capabilities and expanding its scientific team to expedite the development of cutting-edge technologies, progressing the company's platform towards potential clinical applications and broadening its intellectual property portfolio.
About Evis Bioscience
Stage
Seed
Headquarters
Schlieren, Switzerland
Founded
2024
Team Size
6–20
Sectors
biotechgene_therapydrug_deliverynanotechnologymaterialsb2b
Source: https://signalbase.com/